JAK-2 mutations, clinically manifesting as polycythemia vera, essential thrombocythemia, or primary myelofibrosis, carry an increased thrombotic risk, potentially leading to ACS and coronary ischemia [27,28]. Here, JAK2 is linked to acquired polycythemia vera.